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Genome-wide association studies (GWASs) have identified thousands of genetic loci associated with cardiometabolic traits including
type 2 diabetes (T2D), lipid levels, body fat distribution, and adiposity, although most causal genes remain unknown. We used subcu-
taneous adipose tissue RNA-seq data from 434 Finnish men from the METSIM study to identify 9,687 primary and 2,785 secondary cis-
expression quantitative trait loci (eQTL; <1 Mb from TSS, FDR < 1%). Compared to primary eQTL signals, secondary eQTL signals were
located further from transcription start sites, had smaller effect sizes, and were less enriched in adipose tissue regulatory elements
compared to primary signals. Among 2,843 cardiometabolic GWAS signals, 262 colocalized by LD and conditional analysis with 318
transcripts as primary and conditionally distinct secondary cis-eQTLs, including some across ancestries. Of cardiometabolic traits exam-
ined for adipose tissue eQTL colocalizations, waist-hip ratio (WHR) and circulating lipid traits had the highest percentage of colocalized
eQTLs (15% and 14%, respectively). Among alleles associated with increased cardiometabolic GWAS risk, approximately half (53%) were
associated with decreased gene expression level. Mediation analyses of colocalized genes and cardiometabolic traits within the 434 in-
dividuals provided further evidence that gene expression influences variant-trait associations. These results identify hundreds of candi-
date genes that may act in adipose tissue to influence cardiometabolic traits.Introduction
Excess adipose tissue, especially in central abdominal de-
pots, is associated with increased cardiometabolic risk1,2
and mortality.3 Subcutaneous adipose tissue expands to
store additional lipids and serves as a buffering system
for lipid energy balance, especially for fatty acids,4,5
providing a protective role in metabolic risk.6 However,
expansion of adipocyte size, rather than formation
of new adipocytes has also been linked to insulin
resistance.5,7
Genome-wide association studies (GWASs) have identi-
fied thousands of loci for hundreds of human traits, but
most functional variants, genes affected by variants, and
mechanisms remain elusive. Identification of genetic vari-
ants associated with gene expression level (eQTLs) in rele-
vant tissues has proven useful to link non-coding GWAS
variants to plausible candidate genes that may influence
complex traits.8 While 94% of eQTLs are shared across at
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contribute to GWAS traits to identify candidate genes.
Recently, eQTL studies have begun to identify additional
eQTL signals through conditional analysis9–11 in addition
to the more commonly reported primary eQTLs. These
additional conditionally distinct secondary eQTL signals
are widespread and located more distal than primary sig-
nals from the transcription start sites of the associated
genes.9,10 The additional eQTL signals have also been
shown to colocalize with GWAS loci,10 suggesting that
they can detect additional candidate genes.
Previous studies have identified adipose tissue cis-eQTLs
and tested for colocalizations of eQTL signals with cardio-
metabolic GWAS loci.12–15 Additionally, GWASs have re-
ported colocalized subcutaneous adipose cis-eQTLs with
loci for body mass index (BMI), waist-hip ratio (WHR),
WHR adjusted for BMI (WHRadjBMI), type 2 diabetes
(T2D), circulating lipid levels, and adiponectin, a hormone
produced by adipocytes that regulates glucose levels
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presents its own challenges, particularly when the GWASs
and eQTL studies are from different ancestries or when
multiple, conditionally distinct signals exist.
Here, we describe the analysis of subcutaneous adipose
tissue gene expression levels from 434 participants in the
METabolic Syndrome in Men (METSIM) study. METSIM
participants have been well characterized for detailed clin-
ical phenotypes, including metabolic and cardiovascular
traits such as plasma lipids, anthropometric, and glycemic
traits.21 We identified and characterized primary and sec-
ondary cis-eQTL genes that colocalize with GWAS loci for
BMI, cholesterol and triglyceride levels, WHR and
WHRadjBMI, T2D, adiponectin, cardiovascular endpoints,
and other cardiometabolic traits. We further associated
gene expression level with cardiometabolic trait levels in
the METSIM cohort and identify the genes that show the
strongest evidence of mediating the variant to trait
associations.Subjects and Methods
METSIM Study Participants and Sample Characteristics
METSIM is a population-based cohort composed of 10,197 males
of Finnish ancestry from Kuopio, Finland.21 For this analysis, we
used a subset of 550 participants from whom subcutaneous adi-
pose tissue had been collected near the umbilicus by needle bi-
opsy. The METSIM study was approved by the Ethics Committee
of the University of Eastern Finland and Kuopio University Hospi-
tal in Kuopio, Finland and carried out in accordance with the Hel-
sinki Declaration.Written informed consent was obtained from all
participants.
Genotypes were measured using the Illumina OmniExpress
BeadChip array and the Illumina HumanCoreExome at the Center
for Inherited Disease Research (Baltimore, MD). Genotyping qual-
ity control (QC) and imputation to the Haplotype Reference Con-
sortium (HRC) panel22 have been previously described.12 For this
study, we filtered HRC-imputed genotypes to retain 7.8 million
variants withminor allele frequency (MAF)> 0.01 and imputation
quality, r2 > 0.3.RNA Extraction and Sequencing
Following the adipose tissue biopsies, total mRNAwas isolated us-
ing the Qiagen miRNeasy kit (Qiagen), following the manufac-
turer’s instructions. mRNA was isolated with a polyAþ selection
protocol (Illumina TruSeq RNA Sample Preparation Kit v2) and
sequenced on the Illumina HiSeq 2000 platform at the University
of California Los Angeles Neuroscience Genomics Core (UNGC) to
an average sequencing depth of 45million paired-end 50 bp reads.
Readswere filtered using the Fastx-toolkit requiring 80%of bases
to have phred quality > 20. Reads containing linker and adapter
sequences were removed using TagDust (see Web Resources). We
implemented STAR (v.2.4.2a)23 to align reads to the hg19/
GRCh37 human genome reference sequence,24 using GENCODE
v19 (July 2013 freeze) as the annotation. Duplicate reads were re-
tained. Read pairs with unpaired alignments were removed. The
average uniquely mapped reads across all samples was 82.2%.
To ensure RNA samples were matched with the correct geno-
types, we applied MixupMapper,25 verifyBamID,26 and GATK
best practice guidelines (see Web Resources) to call variants fromRNA-seq data and assign best matches between the RNA-seq and
genotype data. We retained samples that matched DNA genotypes
corresponding to the expected self-sample for at least onemethod.Expression Quantification and Sample Level QC
To identify fragments mapping to transcript isoforms, we used
Salmon (v.0.7.2)27 and provided GENCODE v.19 as annotation;
to correct for bias in isoform abundance estimates due to technical
biases resulting from GC content, we used the –gcBias option. Iso-
form abundances were collapsed to the gene-level, and transcript
per million (TPM) values were calculated using tximport
(v.1.0.3).28 To remove genes with limited evidence of expression,
we retained genes with R 5 reads in >25% of samples, resulting
in using 21,735 genes of 57,821 for cis-eQTL analysis.
To assess the tissue heterogeneity of tissue samples, we used the
unmix function in DESeq229 to estimate the percent composition
of whole blood, Epstein Barr virus (EBV)-transformed lympho-
cytes, skeletal muscle, and subcutaneous adipose, using Geno-
type-Tissue Expression (GTEx) v7 median TPM values per tissue
as reference.30 We examined the expression of adipose-specific
genes in three sample sets: all samples (n ¼ 550) and the subsets
comprised of samples with approximately >50% adipose compo-
sition (n ¼ 434) and >75% adipose composition (n ¼ 387).eQTL Mapping
To adjust for the known and unknown technical factors that influ-
ence gene expression estimates, we inverse normal transformed
gene-level TPMs and implemented probabilistic estimation of
expression residuals (PEER)31 and inverse normal transformed
again, since both PEER and eQTL detection require data in a
normal distribution. To optimize for cis-eQTL discovery, we
performed PEER analysis including differing numbers of factors
(k¼ 10 to 90) at intervals of 10.We next performed cis-eQTL detec-
tion using FastQTL (v.2.184)32 on all variants within 1 Mb of the
TSS of each gene and assessed the total number of cis-eQTLs and
the number of genes associated with R1 variant with various
PEER factor values. We selected 60 PEER factors to maximize the
number of cis-eQTLs identified. We next implemented FastQTL
permutation testing to estimate adjusted p values and calculated
the p values corresponding to 1% FDR using the qvalue package
in R (p < 9.6 3 106) to account for genome-wide eQTL testing
of variants within 1 Mb of each transcript and determine the sig-
nificance threshold.
To identify conditionally distinct cis-eQTLs, we first identified
all genes with R1 significantly associated variant at FDR < 1%
and the lead variant for each of these genes. We then included
the dosage values of the lead variant for each gene as a covariate
for eQTL mapping using FastQTL. Conditional secondary eQTLs
were considered significant at FDR < 1% for primary cis-eQTLs
(p < 9.6 3 10-6).
To identify trans-eQTLs, we removed 3,182 pseudogenes33 and
genes with low mappability as these have been observed to in-
crease false positives in distal eQTL analyses.34 We implemented
RSeQC35 to calculate transcript integrity number (TIN),36 the dis-
tribution of deletions across reads, and the distribution of inserted
nucleotides across reads from BAM files. We inverse normal trans-
formed the gene expression for 18,553 remaining genes and
adjusted for TIN, batch, age, insert size, deletion distribution,
and either 0 or 3 PEER factors prior to analysis. To avoid collider
bias, we used limited PEER factors in trans-eQTL mapping.
Using QTLtools (v.1.1),37 we performed association tests for
variants>1Mb away from the transcription start site (TSS); the sig-
nificance threshold for identifying trans-eQTLs was calculated us-
ing the Bonferroni correction (p < 3.4 3 1013).eQTL Validation
For validation, we compared eQTLs with the significant
eQTLs from the GTEx Project V7 release for both subcutaneous
(n ¼ 385) and visceral adipose (n ¼ 313) tissue. For variant-gene
pairs available in both files, we matched the effect alleles to
compare the direction of effect. To ensure that groups of variants
associatedwith the same gene did not inflate replication estimates,
we limited this analysis to the lead variants for each gene in either
METSIM or GTEx.We used the lead variant for each gene from one
study and assessed whether that variant was significant for the
same gene in the other study. We then counted the number of
variant-gene pairs that showed a consistent direction of effect
and met several different p value thresholds between 5 3 103
and 5 3 108 in both studies.eQTL Enrichment in Adipose Tissue Open Chromatin
and Roadmap Adipose Nuclei Chromatin States
We compiled a set of adipose tissue transcriptional regulatory ele-
ments from tissue-derived adipose nuclei chromatin states from
the Roadmap Epigenomics Consortium38 andMETSIM adipose tis-
sue accessible chromatin regions39 generated using an Assay for
Transposase-Accessible Chromatin (ATAC-seq).40 For Roadmap
chromatin states, we used the 18 state chromatin model and
selected promoter states (1_TssA, 2_TssFlnk, 3_TssFlnkU,
4_TssFlnkD, 14_TssBiv) and enhancer states (7_EnhG1, 8_EnhG2,
9_EnhA1, 10_EnhA2, 11_EnhWk, 15_EnhBiv).We defined adipose
tissue accessible chromatin regions as the union of ATAC-seq peaks
across three METSIM subcutaneous adipose samples.39 We also
tested for enrichment among the subsets of ATAC-seq peaks that
overlapped Roadmap adipose nuclei promoters and enhancers,38
requiring that a peak be completely contained within the epige-
nomic region. We pruned eQTL variants based on linkage disequi-
librium (LD, r2> 0.2) using swiss to prevent variants in nominal LD
with each other from inflating enrichment estimates. We selected
background variants using GREGOR;41 variants were matched on
allele frequency, distance to gene, and LD (r2> 0.8; 1000 Genomes
phase 1, in a 1Mbwindow). Backgroundvariantswere thenpruned
with swiss using the same parameters as for significant eQTLs. We
removed background variants that were themselves significant
eQTLs at FDR < 1% (primary or secondary signals) or that were in
high LD (r2> 0.8) with an eQTL lead variant (primary or secondary
signals).We tested for enrichmentusing logistic regression, regress-
ing the eQTL status of a variant (1 ¼ significant eQTL, 0 ¼ not
eQTL), against whether that variant overlapped a given genomic
annotation (1¼ overlapped, 0¼not overlapped). An eQTLor back-
groundvariantwas considered tooverlapagenomicannotation if it
or any of its LD proxies (r2 > 0.8, 1000 Genomes phase 1) overlap-
ped the annotation. Enrichment was defined as the beta of the
regression model, which is the log of the odds ratio that a variant
is an eQTL if it overlaps the given genomic annotation.
To compare the effect sizes of eQTL signals that overlap various
genomic annotations, we used the lead eQTL variant and all vari-
ants in high LD (r2 > 0.8) to identify overlaps with promoters, en-
hancers, and ATAC-seq peaks, stratified by primary and secondary
eQTLs. We then used the effect size of the lead variant of the over-
lapping eQTLs to test for differences in the strength of effect
among different annotations using a Wilcoxon rank sum test.Selection of GWAS Loci and GWAS-eQTL Colocalization
We downloaded the NHGRI-EBI GWAS catalog42 in December
2017 and extracted 4,588 GWAS variants associated with one or
more of 93 cardiometabolic traits (Table S8) at genome-wide signif-
icance (p < 5 3 108) and then added results from five additional
large GWASs for cardiometabolic traits.18,19,43–45 To ensure that
GWAS variants representing the same signal did not inflate coloc-
alization estimates, we performed LD pruning using swiss (seeWeb
Resources) across all traits; variants were ranked by p value, and
variants in LD r2 R 0.8 in METSIM with the lead variant at each
locus were removed.We defined the GWAS risk allele as the variant
associated with a disease state or with the higher quantitative trait
level, except for adiponectin and high-density lipoprotein (HDL)
cholesterol levels, for which we defined the risk effect allele as
associated with a lower trait level as these indicate poorer health
outcomes.
We performed initial colocalization analysis based on LD
between a lead GWAS variant and a lead eQTL variant. We then
performed conditional analysis in the eQTL data by providing ge-
notypes for the lead GWAS variant to FastQTL as a covariate. We
considered signals to be colocalized if (1) the pairwise LD was
high between the GWAS variant and eQTL variants (r2 R 0.8 in
METSIM) and (2) after conditioning on the GWAS variant, the
lead eQTL variant no longer met the 1% FDR equivalent p value
(p > 9.6 3 106).
To identify METSIM variant-gene pairs that were observed in 13
GTEx tissues (n >300 in GTEx v.7; see Table S10 for the tissues
tested), we first determined whether variants of colocalized
variant-gene pairs observed in METSIM were significant eQTLs
in GTEx (FDR < 5%). We next identified the lead eQTL variant
in GTEx and calculated the LD r2 (1000 Genomes, phase 3 EUR)
between the lead GWAS variant and the lead eQTL variant. We
considered these signals to be colocalized if the variants were in
strong LD (r2 R 0.8).
We further performed GWAS colocalizations with METSIM
eQTLs using variants for additional non-cardiometabolic GWAS
traits. For these analyses, we initially used all variants, without
pruning by pairwise LD or distance. We considered signals to be
colocalized if the lead GWAS variant and lead eQTL variant were
in strong LD (r2 R 0.8 in METSIM). After colocalization, we per-
formed LD pruning, removing variants in LD r2 > 0.8 in METSIM
with the lead GWAS variant, to estimate the number of unique
GWAS signals with colocalized eQTLs.
For eQTLs that appeared colocalized with GWAS signals based
on LD, we applied coloc210 to further assess evidence of colocali-
zation. Coloc2 is a Bayesian method that uses summary statistics
to test whether variants underlying a signal are shared between
two studies. For each gene, we included all variants located within
1 Mb of the TSS for which summary statistics were available in
both the GWASs and eQTL studies. Coloc2 estimates the posterior
probabilities of five hypotheses concurrently (H0, no association
signal in either the GWAS or eQTL; H1, only the GWAS has an as-
sociation signal; H2, only the eQTL has an association signal; H3,
both datasets have an association signal, but they are not the
same; H4, the GWAS and eQTL associations signals are colocal-
ized). To make our results more comparable with prior colocaliza-
tion studies, we set prior probabilities for coloc2 to values
comparable to coloc’s46 default settings, rather than allowing the
software to generate its own priors. We used coloc’s default priors
for p1 and p2, the prior probabilities that a variant is causal for
either GWAS or eQTL, respectively (p1 and p2 ¼ 1 3 104). We
set p12, the prior probability that a variant is causal to both
GWAS and eQTL, to 1 3 106. We selected this more conservative
value than coloc’s default p12 prior (1 3 105) because we are
using coloc to provide additional support for conditional analysis
results based on LD and conditional analysis. We evaluated the
posterior probabilities that correspond to H3 and H4, that both
the GWAS and the eQTL have signals, but that they are not the
same (PP3) and that the GWAS and eQTL signals colocalize (PP4),
respectively. We considered the signals to have strong evidence
of colocalization if PP4 > 0.8.Trait-Gene Expression Association
For 287 genes that showed evidence of GWAS signal colocalization
with a primary eQTL signal based on LD and conditional analysis,
we tested for association between gene expression level and each
of the 20 cardiometabolic traits measured in the 434 individuals
(for a list of traits, see Tables S14 and S15). We adjusted traits for
age and gene expression level for TIN, sequencing batch, and
age. Following inverse normal transformation of both trait- and
expression-level residuals, we used linear regression to test for as-
sociation between the gene expression levels and traits. Because
adipose expression level of a large number of genes is associated
with BMI, we also performed these analyses additionally adjusting
both gene expression levels and traits for BMI. The p value corre-
sponding to 5% FDR was calculated using the qvalue package in R.Mediation Analysis
Mediation analyses were conducted in 434 METSIM individuals
using a procedure described by Imai et al.,47 similar to that of
Huang et al.,48 implemented in R and Cþþ, assuming an additive
effect and modified for a continuous outcome. We performed
mediation analyses only when the eQTL and GWAS data were co-
localized and trait data for the GWAS trait itself or a similar trait
was available for METSIM individuals, specifically testing fasting
glucose, fasting insulin, Matsuda index, and HOMA-b for T2D.
We determined the effect of a variant on a trait through the medi-
ator of gene expression, the effect of the variant on the trait when
the mediator is held constant, and the combined effect, which is
the sum of the mediation and variant-trait effects. This method
uses two least squares regression models, where the first model
uses the variant genotype, coded as 0, 1, or 2, as the predictor
and the mediator of gene expression as the response, and the sec-
ond model uses both gene expression level and variant genotype
as predictors and the trait outcome as the response. The mediation
effect was estimated by the product of coefficients from the two
linear regression models. We assumed that the individual effects
were linear and that there is not an interactive effect between
the variant and mediator on the outcome. Confidence intervals
for the mediating effect were calculated using Monte Carlo simu-
lations. We set a ¼ 0:05 and calculated 95% confidence intervals
corresponding to a possible range for the estimates of the effect.
Confidence intervals that did not include 0 were considered evi-
dence of a mediating effect.Results
Analysis of Tissue Heterogeneity
To identify cis-eQTLs for subcutaneous adipose tissue, we
performed RNA-seq on needle biopsy samples obtained
from 550 Finnishmen in theMETSIM study (Table S1). Ad-
ipose tissue is comprised of adipocytes, pre-adipocytes,endothelial cells, and various immune cells,49,50 and nee-
dle biopsies of adipose tissue can include whole blood
and/or muscle. The resulting heterogeneity between
samples can confound the analysis of bulk tissue transcrip-
tomics,51–53 but its effects can be mitigated by tissue de-
convolution methods. We estimated tissue composition
using tissue from GTEx as reference tissue profiles
(Figure S1). We found wide variation in the estimated per-
centage of adipose tissue within our samples. To determine
whether to limit the analysis to higher-purity samples or to
retain the larger sample size including lower-quality sam-
ples, we compared eQTL results from the set of all 550 sam-
ples to subsets of samples with estimated adipose tissue
percentage of approximately >50% (n ¼ 434) and >75%
(n ¼ 387). For all three sample sets, we performed cis-
eQTL analyses with a range of PEER factor corrections us-
ing 7.8M variants and 21,735 genes. We then compared
the strength of association at three previously described
adipose eQTL loci12,13 and counted the total number of
variant-gene associations observed (Tables S2 and S3).
The known eQTLs showed the strongest associations
within the >50% adipose subset (Table S3). The 50% adi-
pose subset also had the most significant cis-eQTL variants
(1.6M versus 1.5M and 1.4M, for the 50%, all, and 75%
sample sets, respectively) and the most variant-gene pairs
(3.0M versus 2.8M and 2.5M, for the 50%, all, and 75%
sample sets, Table S2). These results suggest that the het-
erogeneity between samples in the full sample set of 550
samples and the smaller sample size of the 387 samples
with >75% adipose attenuated the association signals
and that requiring samples to contain>50% adipose tissue
(n ¼ 434) yielded a set of cis-eQTL results that best corre-
spond to adipose tissue; thus, we performed all subsequent
analyses using the subset of 434 samples.
eQTL Identification and Characterization
We performed genome-wide cis-eQTL analyses using 7.8
million genetic variants (MAF> 0.01) from the 434 samples
with>50% adipose tissue and 21,735 genes. Of these, 9,687
genes were associated with at least one variant located
within 1Mbof the TSS (FDR< 1%, p< 9.63 106). The first
and second PEER factors correlated with TIN36 and esti-
mated percent adipose tissue, respectively (Figure S2).
To examine the validity of our results, we compared the
METSIM subcutaneous adipose tissue eQTL results to those
from theGTExproject’s subcutaneous (n¼ 385) and visceral
(n ¼ 313) adipose eQTL analyses. Overall, GTEx detected
fewer cis-eQTLs (FDR < 5%) than METSIM (Table S4). At a
significance threshold of p < 5 3 105, which meets the
FDR < 5% threshold in both studies, 4,442 (95.4%) and
3,370 (96.4%) of the lead eQTL variants identified in
METSIM also showed significant associations with the
same gene and in a consistent direction of effect in the
GTEx subcutaneous and visceral adipose data, respectively.
Combined, these results demonstrated consistency of the
METSIM subcutaneous adipose tissue eQTLs with GTEx
eQTLs.
Figure 1. Comparison of Primary and
Secondary eQTL Association Signals
(A) For each type of transcript (x-axis), the
number of transcripts associated with at
least one nearby variant that met the
genome-wide FDR <1% is shown (y-axis).
(B) Density plot showing the distance from
the lead eQTL variant to the TSS. Dashed
lines represent the median distance to
the TSS for primary (purple) and secondary
(green) eQTLs.
(C) Enrichment of primary and secondary
eQTLs in chromatin marks from Roadmap
adipose nuclei chromatin marks and open
chromatin ATAC-seq peaks from adipose
tissue. The horizontal lines represent the
logistic regression coefficient for enrich-
ment with vertical lines representing
the 95% confidence interval around the
coefficient.
(D) Absolute value of the effect sizes of
eQTL variants that overlap Roadmap adi-
pose nuclei promoters and enhancers.
Black horizontal lines represent the me-
dian effect size for primary and secondary
eQTL variants.Secondary association signals are frequently identified at
eQTL loci and may reflect more complex gene regula-
tion.9,10 Of 9,687 genes that exhibited primary eQTL sig-
nals, 2,785 genes (28.7%) showed a significant secondary
cis-eQTL (FDR < 1%, p < 9.6 3 106). The proportions of
transcript types with primary and secondary cis-
eQTLs were not significantly different from each other
(c2 p ¼ 0.42, Figure 1A). Secondary eQTLs have been
reported to be located farther away from the TSS than pri-
mary eQTLs.9,10 We also observed this pattern: the distri-
bution of distances to TSS for secondary eQTLs
(median ¼ 40.3 kb) was significantly higher than for pri-
mary eQTLs (median ¼ 26.7 kb, Mann Whitney U-test, p
< 2.2 3 1016; Figure 1B). The identification of secondary
eQTL signals in subcutaneous adipose tissue greatly
expanded the set of cis-eQTL signals for available further
investigation.
To characterize the potential function of the primary
and secondary eQTL signals, we evaluated the enrichment
of and effect sizes of the lead variant and LD proxies
compared to adipose nuclei chromatin states (promoters,
enhancers) defined by the Roadmap Epigenomics
Project38 and METSIM adipose tissue open chromatin as
measured by ATAC-seq.39 Lead variants of primary eQTL
signals were more enriched in open chromatin, promoters,
and enhancers than matched control variants, especially
in open chromatin regions within promoters (p < 2 3
10308; b ¼ 2.83). Secondary eQTL variants showed asimilar but weaker pattern of enrich-
ment in all categories, even for a
matched number of eQTL genes
(Table S5; Figure 1C). Further, effect
sizes for primary eQTL variants weresignificantly larger than those of secondary eQTL variants
found within promoters and enhancers (Wilcoxon rank
sum test, p ¼ 4.3 3 10131; Figure 1D). Including both pri-
mary and secondary eQTL variants, effect sizes of variants
within promoters were significantly larger than variants
within enhancers (p ¼ 8.1 3 1012; Figure S3), and effect
sizes of variants within open chromatin in promoters
were significantly larger than promoter variants generally
(p ¼ 3.2 3 105). We observed no significant difference
in the effect sizes between variants within open chromatin
in enhancers and all enhancer variants. These results indi-
cate that eQTL variants within promoters, particularly
those in open chromatin, have larger effects on expression
levels of nearby associated genes than those variants in
enhancers.
To identify variants that influence the expression of
distal genes and contribute to regulatory networks in adi-
pose tissue, we performed a trans-eQTL analysis using
7.8M variants (MAF > 0.01) and 18,553 protein-coding
and lncRNA transcripts, requiring variants to be >1 Mb
away from the TSS. Accounting for the number of tests per-
formed (Bonferroni, p < 3.4 3 1013), we identified
4,432 target genes, and at a relaxed significance threshold
(p < 5 3 108), we identified 13,953 target genes, repre-
senting 24% and 75% of genes tested, respectively (Table
S6). At the known adipose-specific trans-eQTL hub near
KLF14,12,54 which is also a known GWAS locus for HDL-
cholesterol55 and type 2 diabetes (T2D),56 we identified
Table 1. Primary and Secondary eQTLs Colocalized at GWAS Loci








Genes (%) for Which








Genes (%) for Which
the Trait Risk Allele Is
Associated with Decreased
Expression
BMI 310 85 116 60 (52%) 12 11 4 (36%)
All lipids 186 56 62 31 (50%) 7 7 3 (43%)
HDL 73 25 30 18 (60%) 3 3 2 (67%)
LDL 64 16 18 8 (44%) 1 1 0 (0%)
Triglycerides 42 18 19 11 (58%) 2 2 1 (50%)
Total cholesterol 47 13 13 6 (46%) 2 2 1 (50%)
WHRadjBMI 157 48 57 35 (61%) 9 9 5 (56%)
WHR 134 40 49 32 (65%) 6 6 3 (50%)
T2D 115 28 37 20 (54%) 7 8 4 (50%)
Cardiovascular disease 28 9 10 6 (60%) – – –
Adiponectin 11 4 4 2 (50%) – – –
Any trait 874 231 287 152 (53%) 31 31 15 (48%)
Colocalized eQTL (FDR< 1%; p< 9.633 106) among 2,843 GWAS signals (variants clumped by LD r2> 0.8) associated with one or more of 93 cardiometabolic
traits. Each GWAS variant may colocalize with an eQTL for more than one gene. GWAS signals reported for multiple traits are included in counts of colocalized
eQTLs for each trait, so signals and genes are not unique by row. Percentages expressed as the number of genes for which the GWAS risk allele was associated with
decreased expression among all colocalized genes for that trait. No secondary eQTL signals were found to be colocalized with GWAS loci for cardiovascular disease
or adiponectin.rs4731702 as the lead KLF14 cis-eQTL variant and vali-
dated (p < 5 3 108) the distal association of this variant
with expression level of one known target gene, PRMT2,
and two additional target genes, SNX14 and RBBP7, not
previously reported12,54 (Table S7). This male-only
METSIM study detected fewer trans-eQTL associations for
KLF14 than the larger female-only TwinsUK study,54
consistent with power and the reported stronger effects
in females at this locus.57
Colocalization of eQTLs and Cardiometabolic
GWAS Loci
While thousands of cardiometabolic GWAS loci have been
identified, many of the genes underlying these associa-
tions remain unknown. We evaluated cis-eQTLs for evi-
dence of colocalization with 2,843 GWAS signals (variants
clumped by LD r2 R 0.8) associated with one or more of 93
cardiometabolic traits and available in our cis-eQTL data
(Table S8). Of the 2,843 GWAS signals, 874 (30.7%) were
significantly associated with at least one nearby (<1 Mb)
gene at FDR < 1% (Table S9). Using LD and conditional
analysis (see Subjects and Methods), we identified colocal-
izations of 231 GWAS variants with expression of 287
genes, described further below as GWAS-colocalized pri-
mary eQTLs. Of these GWAS-eQTL colocalizations, only
125 (43%) were detected in GTEx subcutaneous adipose
data (GTEx n ¼ 385, FDR < 5%) (Tables S10 and S11).
Among 12 additional tissues with at least 300 samples,
only 59–102 (21%–36%) of these colocalizations were de-
tected (Tables S10 and S11).Colocalized GWAS and eQTL signals suggest potential
candidate genes for cardiometabolic risk. Among the 287
primary eQTL genes colocalized with a GWAS trait, eQTLs
for 116 genes were identified at BMI loci, 62 genes for lipid
traits, 57 genes for WHRadjBMI, 37 genes for T2D, and 10
genes for cardiovascular disease (Table 1). These colocaliza-
tions were based on differing numbers of GWAS signals per
trait; to identify the proportion of GWAS signals with colo-
calized eQTLs for each trait, we compared the total number
of signals reported by five recent GWAS publications for
BMI, lipids, WHR, WHRadjBMI, and T2D, which reported
between 79 and 851 conditionally distinct GWAS signals
per trait, to the number of signals with a colocalized
eQTL signal from those same studies. Across traits from
five studies,18,19,43–45 the proportion of signals found to
be colocalized ranged from 8% for T2D and BMI to 12%
for WHRadjBMI, 14% for all lipids, and 15% for WHR
(Table S12). Among additional non-cardiometabolic
GWAS signals, we observed the highest proportion of colo-
calized signals for blood cell traits and autoimmune
diseases (Tables S13 and S14). These results suggest that ad-
ipose tissue gene expression levels are relevant to a broad
set of cardiometabolic and other GWAS traits, potentially
reflecting the cell types present in adipose tissue.
Genes may influence disease risk by downregulating or
upregulating expression level or function.58 To assess the
direction of effect of GWAS signals on gene expression
level, wematched the GWAS risk alleles to the gene expres-
sion effect alleles (see Subjects and Methods). Across all
primary colocalized loci, the GWAS trait risk allele
Figure 2. Cardiometabolic GWAS and eQTL Colocalizations, Stratified by Trait
Each point represents the lead GWAS variant of a signal colocalized by LD and conditional analysis with an eQTL for the named gene.
Plots show eQTLs at GWAS loci for (A) T2D, (B) WHRadjBMI, and (C) lipids. The x-axis shows chromosomal positions of colocalized
signals and the y-axis shows the log10 p values of the GWAS variant’s association with gene expression level in adipose tissue. After
matching the effect allele from the eQTL study with the risk allele from the GWAS, risk alleles that are associated with increased gene
expression level are shown in red and risk alleles that are associated with decreased gene expression level are shown in blue. Triangles
indicate that more than one gene is colocalized with the GWAS variant (other genes would appear at the same x-axis position). Variants
colocalized as secondary eQTLs are designated by a star after the gene name. Only the strongest associations for the named traits are
shown; full results can be found in Table S9.corresponded to decreased gene expression for 53% of
transcripts (Table 1; Figures 2 and S4), with a range from
44% for LDL loci to 65% for WHR loci. These results
show that for common complex traits, disease risk is asso-
ciated with decreased gene expression level for about half
of all colocalized signals.
We also evaluated secondary eQTL signals for colocaliza-
tion with the initial 2,843 GWAS signals. Of 154 leadGWAS variants associated (FDR < 1%) with a secondary
eQTL signal for at least one nearby gene (Table S15), 31
eQTL signals for 31 transcripts were colocalized at GWAS
loci. Of these, 10 (32.3%) variants showed evidence of co-
localization with at least one primary eQTL gene and with
a different secondary eQTL gene. The other 21 variants
(67.7%) did not demonstrate any evidence of colocaliza-
tion with a primary eQTL signal such that no gene would
Figure 3. A WHRadjBMI Signal Colocalizes with the Secondary
eQTL for DGKQ
Locus plots for the DGKQ locus, colored by two distinct signals
present in the METSIM eQTL data. The lead GWAS variant associ-
ated with WHRadjBMI at this locus,44 rs11724804 (top), is associ-
ated with DGKQ expression but is not in LD with the variant most
strongly associated with DGKQ expression, rs11731377 (eSNP;
middle). After conditional analysis, a second eQTL signal for
DGKQ is apparent and is colocalized with the lead GWAS variant
(bottom). Variants are colored by the strength of their LD with the
lead variant for each signal (diamond), with darker colors indi-
cating stronger LD.have been identified using primary eQTLs alone. We did
not observe the same gene to be colocalized with a
GWAS variant for both a primary and secondary eQTL.
For example, the lead variant rs11724804 from a WHR
and WHRadjBMI locus is not colocalized with the primary
eQTL signal for DGKQ via conditional analysis
(rs11731377; LD r2 ¼ 0.26) but was colocalized with the
secondary eQTL signal for DGKQ, rs13101828, based on
LD and conditional analysis (r2 ¼ 1.0; Figure 3). In hepatic
cells, silencing DGKQ decreased the ability of synthetic
FXR ligand to promote phosphorylation of mTOR, Akt,
and FoxO1,59 and misregulation of the mTOR pathway
has been shown to result in peripheral insulin resistance
and to promote adipogenesis and lipogenesis in adipose
tissue.60 These results suggest that colocalization of sec-
ondary eQTLs can identify substantially more GWAS loci
for which at least one potential candidate gene can provide
insights into GWAS biology, than primary eQTL colocaliza-
tions alone.
For a subset of the 287 GWAS-colocalized primary
eQTLs for which GWAS summary statistics were available
(n ¼ 173; BMI, WHR, WHRadjBMI, and T2D), we further
investigated colocalization of primary eQTL signals by
applying coloc2, a Bayesian colocalization test that uses
summary statistics10,46 (Table S16). Of 173 genes tested,
81 showed strong or moderate evidence of GWAS-eQTL co-
localization (coloc2 posterior probability H4 > 0.8 and
H4 > 0.5, respectively). An additional 82 genes showed
strong or moderate posterior probabilities that did not sup-
port colocalized signals (coloc2 H3 > 0.8 and H3 > 0.5,
respectively), which was especially unexpected for nine
signals with the same lead variant in both the GWAS and
eQTL data and 31 signals with very strong pairwise LD
(r2 > 0.95) between lead GWAS and eQTL variants. A com-
parison of GWAS and eQTL association plots (e.g.,
Figure S5; Table S16) showed the GWAS and eQTL signals
are very similar and suggests that coloc2 is sensitive to
additional nearby GWAS and eQTL signals.
Cross-ancestry Colocalization Analysis
Colocalization methods rely on examining association
patterns in GWAS and eQTL studies for similarity; associa-
tion patterns can differ due to the extent of LD in a region,
which can vary by ancestry. We further examined LD pat-
terns in cis-eQTLs discovered in Finns for a subset of the
BMI GWAS loci that were discovered in individuals from
Japan (Tables S9 and S17, Figure 4). We evaluated the LD
r2 values between the GWAS variant and eSNP in both
the Finnish eQTL population and in East Asian 1000G
data. Of the six loci (corresponding to nine eQTL tran-
scripts) that met the GWAS variant-eSNP colocalization
LD threshold (r2 > 0.8) in Finns, lead variants at four loci
had similar pairwise LD in East Asians and two had lower
LD in East Asians (Table S17).
As an example of similar LD patterns across populations,
the lead BMI-associated variant near GON4L in Japanese
individuals,61 rs860295, was also the lead eSNP for DAP3
Figure 4. Cross-ancestry Comparison of Colocalized GWAS-eQTL Signals
Locus plots showing the regional associations for BMI in Japanese individuals,61 colored by East Asian LD (EAS) (top) and gene expres-
sion in Finns (bottom), colored by Finnish LD.
(A) ADAP3 eQTL signal is colocalized with a BMI signal nearGON4L. The lead variant is shared between the GWAS and eQTL studies and
the patterns of association are similar.
(B) A SULT1A2 eQTL signal is colocalized with a BMI signal near IL27/NUPR1. The LD between the lead eQTL andGWAS variants is low in
East Asians (r2 ¼ 0.22) but high in Finns (r2 ¼ 0.93).(Figure 4A). Similar to previous examples comparing
GWAS and eQTL signals within one ancestry, the similar
patterns of GWAS and eQTL association signals here sug-
gest DAP3 as a candidate gene for the observed association
with BMI. DAP3 has been shown to mediate interferon
gamma-induced cell death,62 which is involved in pro-in-
flammatory responses related to obesity.63 Of note, a
GWAS in Europeans43 also identified BMI-associated vari-
ants in this chromosomal region, although the European
and Japanese GWAS variants exhibited low pairwise LD
(r2 ¼ 0.32 in 1000 Genomes East Asians and r2 ¼ 0.35 in
Finns) and the European signal was not colocalized with
any genes (Table S9). While further characterization of
the locus may identify additional candidate genes, the
shared LD patterns support cross-ancestry conclusions of
colocalized GWAS and eQTL signals.
Two GWAS-eQTL signals we considered to be colocalized
showed high LD (r2 R 0.8) between the lead GWAS and
eSNP in Finns but not in East Asians. The lead GWAS
variant at the IL27/NUPR1 East Asian BMI locus,
rs62034325, is a cis-eQTL for SULT1A2 (p ¼ 1.03 3 1027;
b ¼ 0.67; Figure 4B). LD between the lead GWAS variant
and the eSNP, rs28698667, is high in Finns (r2 ¼ 0.93)
but low in East Asians (r2 ¼ 0.22). However, LD between
the lead GWAS variant and other near-lead eQTL variants(e.g., rs62034322, p ¼ 1.02 3 1027; b ¼ 0.67) is high in
both Finns (r2 ¼ 1.0) and East Asians (r2 ¼ 0.89), and con-
ditional analyses in the eQTL data (pcond ¼ 1.61 3 103)
showed that these signals are colocalized. The SULT1A2
eQTL signal in Finns consists of more variants than the
BMI signal in Japanese, and the BMI-associated variants
appear to be a subset of the eQTL variants. SULT1A2 cata-
lyzes the sulfate conjugation of estrogens, estrogenic alkyl-
phenols, and 17-b-estradiol, to facilitate their removal
from the body,64 and increased levels of 17-b-estradiol are
associated with obesity;65 in addition, SULT1A1 levels
were altered in adipose tissue of rats on a high fat diet.66
These results are consistent with the dependence of all co-
localization methods on patterns of association that vary
by ancestry and suggest that, regardless of GWAS study
ancestry, LD-basedmethods to assess colocalization should
focus on the eQTL study population.
Cardiometabolic Trait Association with Expression Level
of eQTL-GWAS Colocalized Genes
To further investigate the 287 genes identified based on co-
localized primary eQTL-GWAS signals, we tested for associ-
ation of expression level with 20 cardiometabolic traits
measured in the same 434 METSIM individuals. Because





















































































































































































































































































































































































































































































































































































































































percentage (51%) of all genes in our study, we performed
gene-trait associations with and without adjustment for
BMI (Tables S18 and S19). Without adjustment for BMI,
expression levels of 154 genes were associated with at least
one trait, and with adjustment for BMI, expression levels of
49 genes were associated with a trait. The difference be-
tween the analysis with and without adjustment for BMI
may demonstrate the influence of this trait on adipose tis-
sue gene expression levels. This difference also could be
due to gene expression and cardiometabolic traits influ-
encing BMI (collider bias). We recommend caution inter-
preting association results when a gene’s expression level
is associated with BMI (Table S18), as collider bias can alter
the effect size and significance level of the association. The
traits associated with expression level of the most genes
were Matsuda index, WHR, and triglycerides. For example,
at a WHRadjBMI locus, EIF4G2, also known as DAP5,
was significantly associated with fasting free fatty acids
(p ¼ 3.0 3 105) and with Matsuda index, a measure of in-
sulin sensitivity67 (p¼ 7.23 105) (Table S19), and EIF4G2
was not associated with BMI (Table S18), suggesting that
this gene may affect these traits. EIF4G2 is thought to
play a role in the interferon gamma-induced cell death
pathway.68 Association between adipose gene expression
level and clinical traits provides an additional line of evi-
dence that changes in expression of the colocalized genes
may influence quantitative traits and disease risk.
Mediation Analysis
We next evaluated colocalized signals for evidence that
gene expression mediates the effect of a GWAS variant
on a cardiometabolic trait. We estimated the mediating ef-
fect of a variant on a trait level through gene expression
level, adjusted for age, relevant covariates, and BMI (except
when evaluating BMI as an outcome; see Subjects and
Methods for covariates). Of note, observing mediation de-
pends on detecting effects of variants on traits in only 434
individuals. Among the colocalized loci, we tested media-
tion paths only at loci for which a trait comparable to
the reported GWAS signal had been measured in the indi-
viduals with gene expression data; this choice resulted in
testing the same variant and gene for multiple traits in
some cases, leading to more potential mediations than co-
localized signals. Of 348 potential mediations, 90 (25.9%)
showed evidence of gene expression mediating the effect
of an association signal on a trait (the 95% CI of a media-
tion effect, ME, does not include 0; Table S20). We focused
on signals with nominal evidence of the combined effect
of mediation and a direct effect of the GWAS variant on
the trait (p < 0.05, Table 2). Of these, at least four loci
have functions relevant to cardiometabolic traits. For
example, at a well-characterized GWAS locus for adiponec-
tin levels, adipose expression level of CDH13, which en-
codes a receptor for high-molecular-weight adiponectin
multimers,69 mediates the effect of rs12051272 on plasma
adiponectin levels (ME ¼ 0.34; CI [0.086, 0.63]). At
another GWAS locus, MLXIPL (also known as ChREBP)
mediates the variant effect on triglyceride levels (ME ¼
0.12; CI [0.21, 0.40]). In adipose tissue, MLXIPL has
been shown to regulate glucose homeostasis and fatty
acid synthesis.70 In addition, RSPO3 mediates the effect
of rs72959041 on triglycerides (ME ¼ 0.12; CI
[0.21, 0.043]), and RSPO3 activates the Wnt/b-catenin
pathway which promotes angiogenesis,71 suggesting a po-
tential role in the expansion of adipose tissue. Finally,
JAZF1 mediates the effect of rs1708302 on BMI (ME ¼
0.17; CI [0.059, 0.30]); in adipocytes, overexpression of
JAZF1 inhibits lipid accumulation and regulates lipidmeta-
bolism.72 In addition to these well-characterized loci,
expression level of CATSPERZ, also known as TEX40,
mediates an association with BMI (ME¼ 0.23; CI
[0.44, 0.065]), and expression level of ADH1A
mediates an association with WHR (ME¼ 0.01; CI
[0.016, 0.005]). CATSPERZ encodes a calcium ion chan-
nel and ADH1A encodes a member of the alcohol dehydro-
genase family; while neither gene has yet been directly
linked to body size or fat distribution, these mediation re-
sults support the eQTL colocalization and suggest that
these genes play a role in obesity.Discussion
We identified primary and secondary cis-eQTLs in subcu-
taneous adipose from 434 Finnish males from the METSIM
study and linked their gene expression levels to cardiome-
tabolic GWAS signals and measures of 20 cardiometabolic
traits. By colocalizing eQTL signals with 262 cardiometa-
bolic trait GWAS signals, we identified 318 candidate
genes, the highest proportion of which corresponded to
traits with multiple biological pathways relevant to adi-
pose tissue: WHR (15% of GWAS signals), lipids (14% of
GWAS signals), and T2D (8% of GWAS signals). Additional
integration of clinical trait information from the eQTL
study participants through gene-trait association and
mediation analysis provided further support of a role for
these genes in cardiometabolic trait variation.
While GWASs have successfully identified thousands of
genomic regions associated with cardiometabolic diseases
and complex traits, the genes andmechanisms responsible
for many of these loci remain unknown. Identifying candi-
date transcripts for GWAS loci is relatively straightforward
when one of the lead GWAS variants is predicted to cause
a loss of gene function, but identifying candidate genes
with a testable link to function is more ambiguous when
all candidate GWAS variants are noncoding. Colocalized
eQTL signals provide one of several approaches to identify
reasonable candidate genes.73,74 The value of eQTLs derives
from the low prior probability that GWAS variants will by
chance also be functional variants associated with a gene’s
expression level. For our main colocalization analysis, we
assumed that candidate functional variants would be
among those that show the strongest association with
both a GWAS trait and gene expression level. Consistentwith widespread evidence that expression levels of most
genes are regulated by genetic variants,75 31% of lead
GWAS variants in this study showed nominal evidence of
association (FDR < 1%) with expression levels of at least
one transcript. Further evaluation of signal colocalization
using one or more methods46,76–79 is critical, because here
only 1.3% of the associations showed the identical lead
variant to be associated with both the GWAS and gene
expression traits. Interpretation of colocalization can be
challengingas comparisonof signals is affectedby sampling
heterogeneity, the presence of multiple and/or differing
GWAS and eQTL signals per locus, and differences in LD
patterns between GWAS and eQTL study participants.
The use of eQTLs to detect candidate genes at GWAS loci
is becoming more widespread, but colocalizations often
consider only primary eQTL signals, which are most easily
available via summary data. While primary eQTLs identi-
fied 90% of the candidate genes detected here, analysis of
secondary eQTLs detected another 21 genes that would
have been missed by summary level analysis. These sec-
ondary eQTLs may reflect parallel biology with primary
eQTL signals or they may derive from a different underly-
ing cell type present in bulk tissue samples. As eQTL study
sample sizes increase and single-cell or in silico cell-type de-
convolution technologies improve, studies will have more
potential to detect multiple regulatory effects per gene.
Colocalization methods are imperfect and sensitive to
the thresholds applied. In the LD and conditional analysis
approach, we applied a threshold for LD between the
GWAS variant and the eSNP as well as a threshold for evi-
dence of association after conditional analysis. These
thresholds are arbitrary and sensitive to the strength of
the original eQTL signal, the use of lead variants subject
to sampling variability, and a conditional analysis step
that requires individual-level data. In comparison, coloc2
requires setting prior probabilities and thresholds for inter-
preting posterior probabilities and is sensitive to the pres-
ence of multiple signals in either the eQTL or the GWAS
data. Further development of colocalization methods
may improve the use of eQTLs for identifying candidate
genes for GWAS loci.
We provide evidence for cross-ancestry GWAS-eQTL co-
localizations and demonstrated the importance of evalu-
ating colocalization using the LD structure of the eQTL
study population. When the lead variants for the GWAS
and eQTL studies are the same or in high LD in both pop-
ulations, colocalization is straightforward. At these loci,
conditional analysis showed evidence of colocalization.
However, when the LD structure differs substantially be-
tween populations, closer comparison of the patterns of
association in GWAS and eQTL data is required to ensure
that the conclusion of colocalization is warranted. The
results of colocalization across populations can be influ-
enced especially when the pattern of association is
broader due to LD in one population than another and
the selection of a different lead variant within the set of
highly associated variants would result in high LD
between the GWAS variant and eSNP in both ancestries.
Although some loci can be compared cleanly across
ancestries, as eQTL studies in more diverse populations
become available, comparing GWAS and eQTL signals
within ancestries will likely provide stronger evidence of
colocalization.
To further investigate causal relationships between ge-
netic variants and clinical traits, we used the extensive
phenotypic trait information available for the METSIM
eQTL study participants and identified 49 genes associated
with cardiometabolic traits at colocalized GWAS loci.
Although Matsuda index, WHR, and triglycerides showed
the most associations with genes, these traits did not
exhibit the most variation between individuals, suggesting
that even small changes in traits can result in association
with colocalized genes. Because BMI is associated with
nearly half of all genes in our data, the direction of the rela-
tionship between BMI, related traits, and gene expression
is hard to determine; expression level of a gene may affect
BMI, or BMI may influence expression level of a gene and a
trait independently. We further tested for effects of the var-
iants mediated through gene expression on the GWAS trait
or a related trait. The six highlighted mediations (Table 2)
show not only an association between these variants,
genes, and traits, but also a directional, and potentially
causal, path. This mediation analysis method is limited
by statistical power because it uses only the hundreds of in-
dividuals with expression data to detect an effect of the ge-
notype on the trait, whereas thousands of samples were
used to originally detect these associations in GWASs. To
mitigate this limitation, we confined our analysis to estab-
lished GWAS loci and required the combined effect of the
genotype on the trait and the mediation to be significant.
The results of both gene-trait associations and mediation
analysis can be used to guide efforts in functional tests of
genes for mechanistic effects on cardiometabolic traits.
The 318 candidate genes identified here correspond to
GWAS loci across a broad range of cardiometabolic traits.
These genes may act to influence obesity, diabetes, and car-
diovascular traits and should be prioritized for future func-
tional analysis. As larger subcutaneous adipose data sets
become available in diverse ancestries, multiple eQTL sig-
nals will become easier to identify and colocalize with
GWAS signals from across populations.Data Availability
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